SomaLogic signs collaboration deal with Quest:
This article was originally published in Clinica
Boulder, Colorado-based SomaLogic has signed a collaborative agreement with Quest Diagnostics to develop diagnostics tests based on the former's proprietary aptamer array technology platform. SomaLogic is using its protein analysis technology to identify biomarkers in the areas of oncology, cardiovascular, autoimmune and infectious diseases. As part of the agreement, Quest Diagnostics will develop clinical diagnostic tests based on these biomarkers. In addition, Quest Diagnostics, based in Teterboro, New Jersey, has also made a $15m equity investment in SomaLogic. Additional terms of the agreement and a timetable on expected test developments were not disclosed.